2022-002253-26: International treatment-extension study in adult participants with multiple myeloma and who have derived clinical benefit from isatuximab |
|
|
| Completed | 4 | 70 | Europe, RoW | isatuximab, cemiplimab, dexamethasone, lenalidomide, pomalidomide, SAR650984, Concentrate for solution for infusion, Tablet, Capsule, Capsule, hard, Dexamethason 4 mg JENAPHARM®, Dexamethason 8 mg JENAPHARM®, Revlimid® 5 mg, Revlimid® 10 mg, Revlimid® 15 mg, Revlimid® 20 mg, Revlimid® 25 mg, Imnovid® (Pomalidomide) 1 mg hard capsule, Imnovid® (Pomalidomide) 2 mg hard capsule, Imnovid® (Pomalidomide) 3 mg hard capsule, Imnovid® (Pomalidomide) 4 mg hard capsule, Zelvina® 5 mg, Zelvina® 10 mg, Zelvina® 15 mg, Zelvina® 20 mg, Zelvina® 25 mg | Sanofi-aventis recherche & développement, SANOFI-AVENTIS RECHERCHE E DEVELOPPEMENT, Sanofi-aventis recherche & développement, Sanofi-aventis recherche & developpement | Multiple myeloma, Multiple myloma (cancer), Diseases [C] - Cancer [C04] | | | | |
| Not yet recruiting | 4 | 117 | RoW | Isatuximab, bortezomib, lenalidomide, dexamethason, Bortezomib, Lenalidomide, Dexamethasone | Peking Union Medical College Hospital, Handan Central Hospital, Inner Mongolia People's Hospital, The Affiliated Hospital of Qingdao University, Hebei Medical University Third Hospital, North China University of Science and Technology, China-Japan Union Hospital, Jilin University, Cangzhou Central Hospital, Yantai Yuhuangding Hospital, Shengjing Hospital, Second Hospital of Shanxi Medical University, Beijing Chao Yang Hospital, Beijing Jishuitan Hospital, Henan Cancer Hospital, Beijing Hospital, Xuanwu Hospital, Beijing, Shandong Cancer Hospital and Institute | Multiple Myeloma | 07/28 | 01/29 | | |
